{
    "nctId": "NCT01300351",
    "briefTitle": "Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women",
    "officialTitle": "A Randomised, Double-Blind, Parallel-Group, Multicentre Study Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With ER+ Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 249,
    "primaryOutcomeMeasure": "Progression-free Survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal women defined as a woman who has stopped having menstrual periods\n* Breast Cancer has continued to grow after having received treatment with an anti-estrogen hormonal treatment such as tamoxifen or an aromatase inhibitor\n* Requiring hormonal treatment\n* Oestrogen-receptor positive tumour\n* Written informed consent to participate in the trial\n\nExclusion Criteria:\n\n* Treatment with an investigational or non-approved drug within one month\n* An existing serious disease, illness, or condition that will prevent participation or compliance with study procedures\n* A history of allergies to any active or inactive ingredients of fulvestrant (i.e. castor oil)\n* Treatment with more than one regimen of chemotherapy for advanced breast cancer\n* Treatment with more than one regimen of hormonal treatment for advanced breast cancer",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}